Kocabaş, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Özdemir, Ibrahim; Genç, Ömer; Altın, Cihan; Tüner, Haşim; Meriç, Bengisu Keskin; Çoner, Ali

In the following article published in Cardiovascular Drugs and Therapy, December 17, 2022, the subtitle of Table 1 included an incorrect phrase: “For patients receiving rivaroxaban or for patients receiving apixaban or for patients receiving edoxaban.” (Table presented.) Criteria for defining a patient as requiring a reduced dose of direct oral anticoagulants in the ANATOLIA-AF study For patients receiving dabigatran • Age ≥ 80 years • Concomitant usage of verapamil • ≥ 2 of the following criteria: age 75–79 years, GFR 30–50 mL/min/1.73 m2, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving rivaroxaban • GFR 15–49 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving apixaban • ≥ 2 of the following criteria: age ≥ 80 years, serum creatinine ≥ 1.5 mg/dL, or body weight ≤ 60 kg • GFR 15–29 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of diltiazem For patients receiving edoxaban • GFR 15–49 mL/min/1.73 m2 • Body weight ≤ 60 kg • Concomitant usage of strong P-glycoprotein inhibitor (e.g., dronedarone, ketoconazole, erythromycin) • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of verapamil GFR glomerular filtration rate, HAS-BLED uncontrolled hypertension, abnormal renal and liver function (1 point each), stroke, bleeding, labile international normalized ratios, elderly (age > 65 years), drugs or alcohol (1 point each) (concomitant use of antiplatelet agents or non-steroidal anti-inflammatory drugs, alcohol abuse). This has been deleted and replaced with the correction subheading “For patients receiving dabigatran.” Below is Table 1 including this correction.

Kocabaş, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Özdemir, Ibrahim; Genç, Ömer; Altın, Cihan; Tüner, Haşim; Meriç, Bengisu Keskin; Çoner, Ali

Purpose: Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings. Methods: This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association. Results: The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants. Conclusion: The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.